GASTROPARESIS
Delayed gastric emptying in the absence of mechanical gastric outlet obstruction.
Table of Contents
ToggleEpidemiology
- 40–70% mechanically ventilated patients
- Up to 60% septic shock patients
- Common after major surgery
- More common in:
- Head injury
- Stroke
- Burns
- Trauma
- Pancreatitis
- Multiple organ dysfunction
Delayed gastric emptying contributes significantly to
- Underfeeding
- Aspiration pneumonia
- Ventilator-associated pneumonia (VAP)
- Increased ICU stay
Pathophysiology
|
Cause |
Mechanism / Effect on Gastric Emptying |
|
Autonomic dysfunction |
Critical illness causes ↓ vagal tone and ↑ sympathetic activity, leading to fundic dysfunction, weak antral contractions, and pyloric spasm, resulting in delayed gastric emptying. |
|
Inflammatory cytokines |
Sepsis-related TNF-α, IL-1, IL-6, and nitric oxide (NO) suppress gastric smooth muscle activity and impair enteric neurons, reducing gastric motility. |
|
Nitric oxide excess |
Excess NO causes gastric atony, abnormal pyloric relaxation, and loss of coordinated gastric contractions. |
|
Enteric nervous system dysfunction |
Inflammation damages the myenteric plexus and interstitial cells of Cajal, impairing gastric pacemaker activity and coordinated peristalsis. |
|
Hormonal disturbances |
Increased cholecystokinin (CCK), peptide YY (PYY), and GLP-1 inhibit gastric motility and slow gastric emptying. |
|
Hyperglycemia |
Blood glucose >180–200 mg/dL causes antral hypomotility, increased pyloric contraction, and reduced vagal function. This is one of the most important reversible causes; glycemic control often improves gastric emptying. |
|
Electrolyte abnormalities |
Hypokalemia: ↓ smooth muscle contraction. Hypomagnesemia: ↓ neuromuscular transmission. Hypophosphatemia: ↓ ATP production, impairing muscular function. |
|
Drugs |
Most common ICU-related cause. • Opioids (most important): μ-receptor stimulation → ↓ acetylcholine release → ↓ antral contraction + ↑ pyloric tone (e.g., morphine, fentanyl, remifentanil, hydromorphone). • Sedatives: Midazolam > Propofol (mild); Dexmedetomidine has relatively less effect. • Vasopressors (high-dose noradrenaline, vasopressin): ↓ splanchnic perfusion → ↓ motility. • Anticholinergics: Glycopyrrolate, atropine reduce gastric motility. • Calcium channel blockers: May worsen gastric emptying. • GLP-1 receptor agonists: Semaglutide, liraglutide, tirzepatide markedly delay gastric emptying, especially in awake patients. • Dopamine agonists: May impair gastrointestinal motility. |
|
Mechanical ventilation |
High PEEP reduces venous return and splanchnic perfusion; associated sedation further contributes to delayed gastric emptying. |
|
Increased intracranial pressure (ICP) |
Seen in traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and stroke. Autonomic dysfunction results in gastric paralysis (neurogenic gastroparesis). |
Clinical Features
Gastrointestinal
- High GRV
- Vomiting
- Regurgitation
- Nausea
- Fullness
- Bloating
- Abdominal distension
- Epigastric discomfort
Nutritional
- Failure to reach calorie targets
- Protein deficit
- Weight loss
- Muscle wasting
Pulmonary
- Aspiration
- Desaturation
- VAP
- Increased oxygen requirement
Consequences
- Underfeeding
- Protein-energy malnutrition
Diagnosis
1. Clinical Assessment
Evaluate
- Vomiting
- Distension
- High GRVs
- Feeding intolerance
- Bowel sounds (poor predictor)
- Bowel movements
2. Exclude Mechanical Obstruction
Consider
- Gastric outlet obstruction
- Small bowel obstruction
- Volvulus
- Ileus
- Anastomotic complications
Investigations
- CT abdomen
- Contrast study
- Upper GI endoscopy (if indicated)
3. Gastric Residual Volume (GRV)
Historically used but now de-emphasized in modern ICU nutrition guidelines.
Current guideline recommendations
- Routine GRV monitoring is not recommended for all ICU patients because it does not reliably predict aspiration and may unnecessarily interrupt enteral nutrition.
- If GRVs are measured, isolated elevated values should be interpreted in the context of vomiting, regurgitation, abdominal distension, and overall clinical status.
|
GRV |
Interpretation |
|
<250 mL |
Usually acceptable |
|
250–500 mL |
Monitor closely; optimize feeding and consider prokinetics if persistent |
|
>500 mL |
Suggests significant gastric intolerance; evaluate causes and initiate management |
Important: Do not stop feeds based solely on a single elevated GRV in an otherwise asymptomatic patient.
Management
Step 1. Identify Reversible Causes
Correct:
- Hyperglycemia (target generally 140–180 mg/dL in most ICU patients)
- Hypokalemia
- Hypomagnesemia
- Hypophosphatemia
- Dehydration
- Acid-base disturbances
- Sepsis
- Hypoxia
- Hypoperfusion
Review medications:
- Reduce opioids if feasible (multimodal analgesia)
- Minimize deep sedation
- Stop anticholinergics if unnecessary
Step 2. Feeding Optimization
- Elevate head of bed 30–45°
- Continuous feeding rather than bolus feeding
- Slow advancement of feed rate
- Avoid overfeeding
- Consider lower-fat formulas if appropriate
- Flush feeding tubes regularly
- Ensure correct tube position
3. Pharmacological Therapy
Metoclopramide + erythromycin is more effective than either agent alone in patients with persistent intolerance but should generally be limited to short courses because of tachyphylaxis and adverse effects.
|
Parameter |
Metoclopramide |
Domperidone |
Erythromycin |
Levosulpiride |
|
Mechanism |
|
Peripheral D₂ antagonist |
|
|
|
Dose |
10 mg IV every 6–8 hours (reduce dose in renal impairment) |
|
200–250 mg IV every 6–8 hours |
25 mg three times daily |
|
CNS Side Effects |
Yes (crosses BBB) • Dystonia •Parkinsonism
|
Minimal (does not cross BBB significantly) |
None specific |
Low but possible EPS |
|
Serious Warning |
⚠ Black box warning: Tardive dyskinesia ➡ Use ≤12 weeks |
QT prolongation, arrhythmia risk,Hyperprolactinemia |
QT prolongation, drug interactions (CYP3A4) |
Hyperprolactinemia, QT prolongation |
Other Agents
|
Drug |
Role |
|
Prucalopride |
5-HT₄ agonist; limited ICU evidence |
|
Neostigmine |
Reserved for acute colonic pseudo-obstruction, not isolated gastroparesis |
|
Ghrelin agonists (e.g., relamorelin) |
Investigational |
|
Cisapride |
Withdrawn in many countries because of arrhythmias |
|
Bethanechol |
Rarely used |
Step 4. Post-Pyloric Feeding
Indications include:
- Persistent intolerance despite prokinetics
- Recurrent aspiration
- Recurrent vomiting
- GRV persistently >500 mL with inability to meet nutritional goals
- Severe pancreatitis
- High aspiration risk
Options:
- Nasojejunal tube
- Naso-duodenal tube
- PEG-J (long-term)
Benefits:
- Improves delivery of enteral nutrition
- Reduces vomiting and regurgitation
- May reduce aspiration in selected patients
Step 5. Parenteral Nutrition
Consider supplemental or total PN when:
- Enteral nutrition remains insufficient despite optimization
- Post-pyloric feeding is not feasible or unsuccessful
- There are contraindications to enteral nutrition
Step 6. Gastric Decompression
Useful in patients with:
- Marked gastric distension
- Persistent vomiting
- High aspiration risk
- Gastric outlet obstruction while awaiting definitive therapy
Step 7. Surgery or Endoscopic Intervention
Rarely required in ICU unless there is:
- Mechanical obstruction
- Gastric volvulus
- Ischemia
- Perforation
- Refractory chronic gastroparesis requiring specialized interventions (e.g., G-POEM or gastric electrical stimulation) after recovery from critical illness
